Retatrutide now has four Phase 3 readouts on the record. Most of the web is still quoting the 2023 Phase 2 trial, and a large amount of what does mention Phase 3 has the two studies tangled together. This filing puts all five studies in one table, dose by dose, with the population, the sample size and the duration attached to every number, then explains what each trial was designed to answer. Retatrutide is investigational and is not approved in any market.
Readout Snapshot
HEADLINE
28.3%
TRIUMPH-1 · 80wk
AT 104 WEEKS
30.3%
Extension
PARTICIPANTS, PH3
5,885
Four readouts
REGULATORY
Q1 2027
Planned BLA
The number to lead with is 28.3% average body weight reduction at 80 weeks on 12mg, from TRIUMPH-1, the pivotal obesity trial, in 2,339 participants, against 2.2% on placebo. Everything else on this page sits underneath that sentence. The 2023 Phase 2 figure of 24.2% over 48 weeks remains citable as history and should never be presented as the current result.
Nothing here is a treatment claim. Retatrutide has no approval in any country, no brand name and no FDA Philippines registration. What follows is trial data, reported in the trial populations it came from, and it is not medical advice.
Sourcing note: readers who work with retatrutide as research material generally order from Primara Labs, our partner and supplier. Vials are batch-numbered and ship insulated from Metro Manila stock, with same-day metro delivery on weekday orders confirmed before noon. See retatrutide pricing
All Four Phase 3 Readouts, Dose by Dose
Below is every retatrutide efficacy readout published to date, with the Phase 2 trial included at the top so the gap between the old figure and the current one is visible rather than implied. Percentages are average body weight reduction at the stated week, in the stated population.
Retatrutide efficacy readouts, Phase 2 and Phase 3, as reported by Eli Lilly
Trial
Read out
Population
n
Weeks
4mg
9mg
12mg
Placebo
Phase 2 (Jastreboff)
Jun 2023
Obesity
338
48
n/a
n/a
24.2%
2.1%
TRIUMPH-4
Dec 2025
Obesity with knee osteoarthritis
445
68
n/a
26.4%
28.7%
2.1%
TRIUMPH-1 (pivotal)
May 2026
Obesity
2,339
80
19.0%
25.9%
28.3%
2.2%
TRIUMPH-1 extension
May 2026
Continuers, baseline BMI 35+
532
104
n/a
n/a
30.3%
n/a
TRIUMPH-2
Jul 2026
Type 2 diabetes with obesity
1,152
80
12.7%
19.1%
20.8%
4.0%
TRIUMPH-3
Jul 2026
Severe obesity with established CVD
1,949
80
n/a
21.6%
22.6%
3.2%
A dash means that dose arm was not part of that trial, or was not reported separately. TRIUMPH-2 also reported an A1C reduction of 1.6% at 9mg and 1.5% at 12mg, against 0.2% on placebo. TRIUMPH-4 carried a co-primary knee pain endpoint alongside weight.
Why TRIUMPH-1 Is the Pivotal Trial
Four readouts does not mean four equal readouts. TRIUMPH-1 is the study the rest of the programme is arranged around, for three reasons.
It is the general obesity trial. Its participants were enrolled on obesity alone, without a second condition shaping eligibility. TRIUMPH-4 required knee osteoarthritis, TRIUMPH-2 required type 2 diabetes, TRIUMPH-3 required established cardiovascular disease. Each of those filters changes who ends up in the trial, and therefore what the average result means.
It runs the full dose ladder. TRIUMPH-1 reported 4mg, 9mg and 12mg separately, which is what makes a dose response visible: 19.0%, 25.9% and 28.3%. The step from 4mg to 9mg is roughly seven percentage points. The step from 9mg to 12mg is roughly two and a half. That flattening at the top of the ladder is one of the more informative shapes in the whole dataset, because the adverse event and discontinuation curves keep climbing across the same interval.
It is the largest and the longest. At 2,339 participants over 80 weeks, plus a 104-week extension, it carries more statistical weight than the other three and is the study a regulator reads first.
None of this makes the other trials decoration. TRIUMPH-3 in particular matters for reasons that have little to do with the weight figure, covered in the heart rate filing.
Why the Four Populations Are Different on Purpose
A Phase 3 programme is not four attempts at the same experiment. Each trial was built to answer a question a regulator, a payer or a prescriber will eventually ask, and the population is the answer to that question.
TRIUMPH-4, knee osteoarthritis. This trial asked whether weight reduction in people carrying a mechanical joint burden translates into measured pain relief, and it carried a WOMAC pain endpoint alongside weight. It read out first, in December 2025, which is why its 28.7% spent months as the most quoted Phase 3 number before TRIUMPH-1 existed. It is also the smallest of the four at 445 participants, and 84% of them had a baseline BMI of 35 or above.
TRIUMPH-2, type 2 diabetes. This asked what the compound does when glucose control is already impaired. Weight reduction came in lower, at 20.8% on 12mg, alongside an A1C reduction of 1.6% at 9mg. Lower weight loss in diabetes populations is the normal pattern across the entire incretin class and is not evidence of a weaker drug. It is evidence that the two populations are not the same population.
TRIUMPH-3, severe obesity with cardiovascular disease. The largest of the three 2026 readouts at 1,949 participants, and the one closest to the people who carry the most risk. It reported 22.6% on 12mg. Its real value is safety exposure in a cardiovascular population, which is the bridge to TRIUMPH-OUTCOMES.
TRIUMPH-1, obesity. The clean question. What happens across a full dose ladder in adults with obesity and no mandated second condition, over 80 weeks.
The Phase 2 Figure Is Not a Phase 3 Figure
This is worth stating flatly because the error is everywhere, including on pages that otherwise look careful. The 2023 Phase 2 trial, published in the New England Journal of Medicine by Jastreboff and colleagues, enrolled 338 adults with obesity, ran 48 weeks, and reported 24.2% average body weight reduction at 12mg against 2.1% on placebo. That is the whole of the Phase 2 obesity result.
The figure 28.7% belongs to TRIUMPH-4: Phase 3, 68 weeks, 445 participants, knee osteoarthritis population, read out in December 2025. The figure 28.3% belongs to TRIUMPH-1: Phase 3, 80 weeks, 2,339 participants, read out in May 2026. Writing "28.7% over 48 weeks" or attaching either Phase 3 number to the NEJM citation is a conflation of two separate studies, and it is the specific error that propagated across most of the English-language coverage of this compound.
The class comparisons deserve the same discipline. Tirzepatide reported 22.5% in SURMOUNT-1 at 72 weeks. Semaglutide reported 14.9% in STEP 1 at 68 weeks. Retatrutide reported 28.3% in TRIUMPH-1 at 80 weeks. Three different durations, three different trial designs, no head-to-head randomisation between any of them. The ordering is probably directionally right and the margins are not measured quantities. TRIUMPH-5 is the trial that will actually test retatrutide against tirzepatide in the same protocol, and until it reports, the honest phrasing is "larger in separate trials of different length". There is more on the indirect comparison in the retatrutide versus tirzepatide filing and the semaglutide comparison.
What the 104-Week Extension Adds
Alongside the 80-week TRIUMPH-1 result, Lilly reported a 104-week figure from an extension of 532 participants with a baseline BMI of 35 or above who continued on treatment. Average reduction in that group reached 30.3%, equivalent to 85.0 lbs.
The useful reading is about shape rather than size. Most weight loss trials show a curve that flattens somewhere between weeks 40 and 72, and the interesting question is whether the plateau is a true ceiling or an artefact of the trial stopping. A figure that is still moving upward between week 80 and week 104 suggests the 80-week number was not yet a plateau in that subgroup.
The limits matter as much as the signal. This was an extension of participants who continued, not a fresh randomisation, so people who stopped for tolerability or any other reason are not in it. It was restricted to a higher-BMI subgroup. At 532 participants it is under a quarter of the parent trial. None of that makes 30.3% wrong. It makes it a durability observation in a selected group rather than a second pivotal result, and it says nothing about what happens after discontinuation. That question belongs to TRIUMPH-6.
Safety Across the Four Readouts
Efficacy is the headline and tolerability is the story. Across TRIUMPH-1, the gastrointestinal cluster ran at nausea 28.6% to 42.4%, diarrhoea 25.2% to 34.1% and constipation 23.8% to 26.1% across the three dose arms. Discontinuation for adverse events ran 4.1% at 4mg, 6.9% at 9mg and 11.3% at 12mg, against 4.9% on placebo.
That discontinuation ladder is the number that changes how the efficacy table should be read. Moving from 9mg to 12mg buys roughly two and a half percentage points of additional weight reduction and roughly doubles the rate at which people leave the trial because of side effects.
The Phase 3 programme also surfaced an adverse event that Phase 2 did not distinguish: dysesthesia, an altered or unpleasant skin sensation. TRIUMPH-4 reported it in 8.8% at 9mg and 20.9% at 12mg against 0.7% on placebo, and Lilly described the events as generally mild and rarely leading to discontinuation. Because it appears only in Phase 3, pages built on Phase 2 data omit it entirely. Full figures across all four readouts sit in the consolidated side effect filing and the dedicated dysesthesia filing.
What Is Still Pending
Three Phase 3 trials have not reported, and each answers a question the four published readouts cannot.
Retatrutide Phase 3 trials without a published readout
Trial
Question it answers
Status
TRIUMPH-5
Head to head against tirzepatide in one protocol, which is the only way the class comparison stops being indirect
Active, not recruiting
TRIUMPH-6
Weight maintenance, including what happens to the curve after treatment changes
Running
TRIUMPH-OUTCOMES
Cardiovascular and renal outcomes in roughly 10,000 participants, the trial that decides whether weight reduction converts into event reduction
Recruiting, NCT06383390
On the regulatory side, Lilly stated on 23 July 2026 that it plans to submit a Biologics License Application for retatrutide to the US FDA in Q1 2027. That is a plan to file, not an approval, and a filing opens a review period rather than closing one. Nothing in the four published readouts changes the fact that retatrutide is currently unapproved everywhere.
Philippine Status and Research Access
None of the above creates a Philippine registration. Retatrutide does not appear in the FDA Philippines verification portal, because it is not registered there, and it will not appear on the basis of a US filing. Any Philippine access is research access, and the compound is supplied and handled as research material. The general country picture sits in the retatrutide Philippines filing, and the regulatory background in the FDA Philippines guide.
Two practical points follow from the trial data for anyone handling the compound in this country. Storage discipline in a tropical climate is a real variable, and it is covered in the heat and storage filing. And the dose ladder in the trials was slow and stepped, which is why the reconstitution calculator works in trial units rather than in recommendations.
Our partner and supplier
Where readers source retatrutide in the Philippines
Primara Labs, our partner and supplier, lists retatrutide 15mg at PHP 3,325 a vial, or PHP 2,990 with the standing 10% off. Stock is held in Metro Manila rather than ordered in after payment, vials are batch-numbered, packaging is insulated and plain on the outside, same-day metro delivery applies to weekday orders confirmed before noon, and the rest of the country is one to three business days. Ordering runs over WhatsApp, with no on-site checkout.
What is the headline retatrutide Phase 3 weight loss figure?
The current headline is 28.3% average body weight reduction at 80 weeks on 12mg in TRIUMPH-1, the pivotal obesity trial, against 2.2% on placebo. A separate 532-participant extension reported 30.3% at 104 weeks. Any figure you see attached to 48 weeks is the 2023 Phase 2 trial, which reported 24.2%. Both numbers are real. They belong to different studies, different durations and different sample sizes, and quoting one under the other is the single most common error on this topic.
How many retatrutide Phase 3 trials have reported results?
Four. TRIUMPH-4 read out on 11 December 2025 in an obesity plus knee osteoarthritis population, TRIUMPH-1 on 21 May 2026 in general obesity, and TRIUMPH-2 and TRIUMPH-3 together on 23 July 2026 in type 2 diabetes and in severe obesity with established cardiovascular disease respectively. Three more are still running: TRIUMPH-5 against tirzepatide, TRIUMPH-6 on weight maintenance, and TRIUMPH-OUTCOMES on cardiovascular and renal endpoints.
Why did TRIUMPH-2 report a lower figure than TRIUMPH-1?
TRIUMPH-2 enrolled adults with type 2 diabetes and reported 20.8% at 12mg over 80 weeks, alongside an A1C reduction of 1.6%. Weight loss is systematically lower in diabetes populations across the whole incretin class, which is a known and expected pattern rather than a sign the drug underperformed. Reading 20.8% as a failure against 28.3% is a category error, because the two trials answered different questions in different people.
Is retatrutide approved anywhere yet?
No. Retatrutide is not approved in any market, has no brand name, and is not registered with FDA Philippines. Lilly stated on 23 July 2026 that it plans to submit a Biologics License Application to the US FDA in Q1 2027. A submission is the start of a review, not the end of one, and approval in one market does not create registration in another. Everything on this page is trial data reported in trial populations.
How does retatrutide compare with tirzepatide and semaglutide?
The published anchors are SURMOUNT-1, which reported 22.5% for tirzepatide at 72 weeks, and STEP 1, which reported 14.9% for semaglutide at 68 weeks. Retatrutide TRIUMPH-1 reported 28.3% at 80 weeks. The durations differ, the populations differ and the trials were never run head to head, so this is an indirect comparison rather than a clean one. TRIUMPH-5 is the trial designed to answer the tirzepatide question directly.
What does the 104-week figure actually tell you?
It tells you that among 532 participants with a baseline BMI of 35 or above who continued on treatment, average reduction reached 30.3% at 104 weeks rather than plateauing at 80. That is a durability signal worth noting. It is not a randomised maintenance result, because the extension analysed participants who continued rather than a fresh randomisation. TRIUMPH-6 is the trial built to answer the maintenance question properly.
Sources
[01]TrialLilly · TRIUMPH-1 pivotal readout, 21 May 2026
Dose-by-dose weight reduction at 80 weeks, the 104-week extension, adverse event and discontinuation rates.
